Pamufetinib mesylate (Synonyms: TAS-115 mesylate)
目录号: PL02657 纯度: ≥99%
CAS No. :1688673-09-7
商品编号 规格 价格 会员价 是否有货 数量
PL02657-5mg 5mg ¥3214.00 请登录
PL02657-10mg 10mg ¥5625.00 请登录
PL02657-50mg 50mg ¥14465.00 请登录
PL02657-100mg 100mg ¥24109.00 请登录
PL02657-200mg 200mg 询价 询价
PL02657-500mg 500mg 询价 询价
PL02657-10mM*1mLinDMSO 10mM*1mLinDMSO ¥4339.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
Pamufetinib mesylate
中文别名
4-(2-氟-4-(3-(2-苯基乙酰基)硫脲基)苯氧基)-7-甲氧基-N-甲基喹啉-6-甲酰胺甲磺酸盐;化合物 T13108L
英文名称
Pamufetinib mesylate
英文别名
TAS-115 mesylate;TAS-115 Methanesulfonic acid salt;TAS-115 mesylate (Synonyms: TAS-115 methanesulfonate);TAS115;TAS 115;TAS-115 methanesulfonate;TAS-115 mesylate (TAS-115 methanesulfonate);Pamufetinib (mesylate);Pamufetinib mesylate
Cas No.
1688673-09-7
分子式
C28H27FN4O7S2
分子量
614.67
包装储存
4°C, sealed storage, away from moistur In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
产品详情
Pamufetinib (TAS-115) mesylate是一种有效的 VEGFR 和肝细胞生长因子受体 (c-Met/HGFR) 的靶向激酶抑制剂,能够抑制 rVEGFR2 和 rMET 的活性,IC50 值分别为 30 和 32 nM。
生物活性
Pamufetinib (TAS-115) mesylate is a potent VEGFRand hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor, with IC 50 s of 30 and 32 nM for rVEGFR2 and rMET, respectively.
性状
Solid
IC50 & Target[1][2]
IC50: 30 nM (rVEGFR2), 32 nM (rMET)
体外研究(In Vitro)
Pamufetinib mesylate powerfully suppresses the VEGF-dependent proliferation of HUVECs (IC50=0.019 μM) as a VEGFR-targeted inhibitor and powerfully suppresses the proliferation of MET-amplified cancer cells (GI50=0.032-0.362 μM) as a MET-targeted inhibitor. Pamufetinib mesylate has much less toxicity in various normal cell lines when compared with other VEGFR-targeted kinase inhibitors. Crizotinib and Pamufetinib mesylate inhibit Met phosphorylation and reverse erlotinib resistance and VEGF production triggered by HGF in PC-9 and HCC827 cells. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
Pamufetinib mesylate completely suppresses the progression of MET-inactivated tumor by blocking angiogenesis without toxicity when given every day for 6 weeks, even at a serum-saturating dose of Pamufetinib mesylate. Pamufetinib mesylate induces marked tumor shrinkage and prolonges survival in MET-amplified human cancer–bearing mice. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
4°C, sealed storage, away from moistur In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
ClinicalTrial
参考文献
[1]. Fujita H, et al. The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile. Mol Cancer Ther. 2013 Dec;12(12):2685-96.
[2]. Nakade J, et al. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation. J Thorac Oncol. 2014 Jun;9(6):775-83.
溶解度数据
In Vitro: DMSO : 75 mg/mL (122.02 mM; Need ultrasonic)配制储备液
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2